Relationship between fatigue, subclinical systemic inflammation, and lung function parameters in patients with sarcoidosis remission.

<bold>Introduction:</bold> Chronic fatigue is prevalent in 50-70% of sarcoidosis patients in active disease and can persist in remission. <bold>Aim and objectives:</bold> This study explores the connection between fatigue, subclinical systemic inflammation, and lung function in sarcoidosis, particularly during remission. <bold>Methods:</bold> Three patient groups were formed: · Group 1 (22 patients) with remission and fatigue. · Group 2 (26 patients) with active sarcoidosis. · Group 3 (23 patients) with remission and no fatigue. Systemic inflammation was assessed through hsCRP, IL-6, and TNF-alpha, while oxidative stress was measured by 8-isoprostane concentration and serum antioxidant activity. Clinical, radiological, and functional assessments, along with FAS (Fatigue Assessment Scale) and BDI (Beck Depression Inventory) questionnaires, were conducted for each patient. <bold>Results:</bold> The study showed higher hsCRP in the fatigue group (7893.49 ng/ml) compared to no fatigue (4582.52 ng/ml, p=0.02). The subjective fatigue patients also exhibited elevated 8-isoprostane (422.84 ng/ml vs. 409.25 ng/ml, p=0.047). IL-6 was significantly higher in the FAS ≥22 group (8.07 ng/ml) than FAS <22 (6.64 ng/ml, p=0.007). IL-6 correlated positively with FAS (r=0.33, p=0.008) and BDI (r=0.33, p=0.007).< Patients in remission with fatigue and active sarcoidosis had lower FEV1 and FVC values than those in remission without fatigue. <bold>Conclusions:</bold> Subclinical inflammation may contribute to fatigue in remission, but lung dysfunction is not associated with fatigue in sarcoidosis remission.